Conference Day Two

Cancelled

7:50 am Check-In & Coffee

8:50 am Chair’s Opening Remarks

Enhancing Safety & Durability of Cell Therapies Using Inducible & Logic-Gated Constructs

9:00 am Engineering Precision & Control in Logic-Gated CAR-T Cell Design

Synopsis

  • Exploring the design and development of logic-gated CAR-T cell constructs to enhance specificity, safety, and efficacy
  • Discussing the integration of multiple signaling domains and activation thresholds to achieve precise control over CAR-T cell function
  • Evaluating the potential of logic-gated CAR-T cells to overcome challenges associated with on-target, off-tumor toxicity and persistence

9:30 am Prolonging Persistence & Enhancing Safety Through Inducible & Armoring Strategies

  • Nicholas Frankel Associate Director-Gene Circuit Discovery, Senti Biosciences Inc.

Synopsis

  • Investigating the role of inducible promoters and synthetic circuits in regulating CAR-T cell activation and persistence
  • Exploring various armoring strategies to protect CAR-T cells from the immunosuppressive tumor microenvironment and enhance their therapeutic efficacy
  • Discussing the combination of inducible and armoring approaches to create highly potent and safe CAR-T cell therapies

10:00 am Expert Discussion – Translating Inducible & Logic-Gated Cell Therapies to the Clinic

Synopsis

  • Addressing the challenges and opportunities associated with translating inducible cell therapies to clinical application
  • Discussing the development of appropriate clinical trial designs and endpoints to evaluate the safety and efficacy of these advanced cell therapies
  • Exploring the potential of patient-specific factors and biomarkers to optimize the selection and treatment of patients with inducible and logic-gated cells

10:30 am Morning Refreshments & Speed Networking

Addressing the Preclinical & Clinical Landscape of Complex Engineering to Treat Solid Tumours

11:00 am Advancing Engineered TIL (eTIL®) Therapies for the Treatment of Solid Tumors

Synopsis

  • Exploring approaches to edit multiple T-cell targets for enhanced therapeutic efficacy against solid tumors
  • Immune CRISPRomics® Platform discovered SOCS1 and Regnase-1 as top gene targets enhancing T-cell anti-tumor function
  • Developing single and dual-edited eTIL® therapies with inactivation of SOCS1 and Regnase-1

11:30 am A Safer and More Efficacious Cell Therapy Construct for Solid Tumors

  • Cheng Liu President & Chief Executive Officer, Eureka Therapeutics

Synopsis

  • Showcasing a head-to-head comparison “ARTEMIS vs CAR Technology” in T-cell therapy against solid tumors
  • Targeting Glypican 3 (GPC3) in advanced hepatocellular carcinoma (HCC)
  • Designing ARTEMIS Antibody TCR (AbTCR) T-cells to overcome major hurdles in treating solid tumors
  • Infiltrating solid tumors in an immunosuppressive microenvironment
  • Demonstrating superior safety and efficacy of ARTEMIS T cells

12:00 pm Panel Discussion: Translating Complex Cell Therapies into Clinical Success for Solid Tumors

  • Junchen Gu Associate Director, AstraZeneca
  • Cheng Liu President & Chief Executive Officer, Eureka Therapeutics

Synopsis

  • Sharing insights and challenges from the forefront of developing complex cell therapies for solid tumors
  • Discussing strategies to enhance cell therapy efficacy and overcome the complex tumor microenvironment
  • Analyzing clinical data to inform future development and optimization of complex cell therapy approaches

1 pm Lunch Break & Networking

Emerging Technologies & Applications for Complex Cell Therapy Bioengineering

2:00 pm Audience Discussion: Engineering Robust & Scalable Manufacturing Processes for Complex Cell Therapies

  • Amish Patel Senior Vice President - Technical Operations, Calidi Biotherapeutics Inc.

Synopsis

  • Developing standardized, reproducible, and scalable manufacturing processes for complex bioengineered cell therapies
  • Addressing the challenges of incorporating advanced cell engineering techniques into GMP-compliant manufacturing environments
  • Optimizing process parameters and quality control measures to ensure product consistency and potency

2:30 pm Opportunities for Complex Bioengineering Approaches to Bring Benefits to Autoimmune Patients

Synopsis

  • Developing engineered cell therapies with enhanced specificity and control to target pathogenic immune cells while preserving healthy immune function
  • Designing cell therapies capable of inducing targeted immune tolerance to prevent autoimmune attacks and maintain long-term disease remission

3:00 pm What’s Next for Complex Bioengineering Approaches to Cell Therapy?

  • Henri Bayle Chief Scientific Officer, NKILT Therapeutics

Synopsis

  • Exploring novel engineering approaches for next-generation CAR constructs and current bottlenecks for current technologies
  • Exploring the commercial potential of integrating CRISPR and synthetic biology to develop next-generation CAR-T products with enhanced efficacy and safety
  • Investigating the future potential of multi-functional cell therapies

3:30 pm Chair’s Closing Remarks

3:40 pm End of Conference